View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 7, 2022

First Wave BioPharma concludes enrolment in Covid-19-related GI drug trial

The two-part, placebo-controlled trial will confirm FW-COV’s safety and ability to remove the virus from the GI tract.

First Wave BioPharma has concluded participant enrolment for the second part of the Phase II RESERVOIR clinical trial of its oral tablet, FW-COV, for treating gastrointestinal (GI) infections associated with Covid-19.

A total of 150 subjects were enrolled in the second part of the trial.

An oral formulation of micronised niclosamide, FW-COV is being developed for eliminating the SARS-CoV-2 virus from the GI tract.

Niclosamide is a prescription small molecule drug listed by the World Health Organization (WHO) as an essential therapeutic.

The two-part, two-arm, placebo-controlled, randomised trial will confirm FW-COV’s safety and evaluate its ability to eliminate the virus from the digestive tract.

Subjects enrolled in the second part of the trial were given either FW-COV or a placebo for 14 days and will be followed up for six weeks on concluding the treatment.

In the trial subjects, no drug-associated serious adverse events following treatment with FW-COV were observed.

Top-line results from the trial are expected in the first half of this year.

First Wave BioPharma president and CEO James Sapirstein said: “Based on the positive safety data observed thus far, combined with earlier published in vitro Covid efficacy data for niclosamide, we believe that FW-COV has the potential to contribute to the global need for new therapies against SARS2.

“Furthermore, because niclosamide targets the entire virus and not just the spike protein, we believe that FW-COV may prove effective against multiple strains of Covid-19, including the Delta and Omicron variants.”

The company plans to seek Emergency Use Authorization (EUA) this year if the Phase II trial is successful.

Institut Pasteur Korea recently identified niclosamide as a potent SARS-CoV-2 inhibitor possessing a 40-fold increased potency as against remdesivir.

Last November, an independent data monitoring committee recommended First Wave BioPharma to continue subject enrolment in the second part of the Phase II RESERVOIR trial of FW-COV to treat Covid-19 related GI infections.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena